Compare iShares MSCI ACWI ETF (ACWI) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI ACWI ETF vs GSK plc — how do they compare? iShares MSCI ACWI ETF trades at $160.86, while GSK plc trades at $50.33 (market cap $102.60B). The key difference: GSK plc pays a 3.57% dividend while iShares MSCI ACWI ETF pays none, and iShares MSCI ACWI ETF is trading nearer its 52-week high, GSK plc nearer its low. Which is the better fit depends on your goals.
| ACWI | GSK | |
|---|---|---|
52-Week High | $161.44 | $61.18 |
52-Week Low | $132.04 | $38.22 |
Market Cap | — | $102.60B |
Sector | — | Health |
Enterprise Value | — | $123.04B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACWI trades at $161.65, up 0.34% today, with strong technical momentum showing bullish moving average signals. The ETF benefits from robust global earnings growth and investor inflows into equity ETFs, particularly in technology sectors. Recent institutional activity includes Bank of New York Mellon adjusting its position, while technical indicators show overbought conditions with RSI above 74.
The outlook remains positive given strong EPS growth and reasonable valuation at 15.5x forward P/E. Key risks include overbought technical conditions and market concentration in technology. Institutional sentiment appears constructive with continued ETF inflows supporting the global equity rally.
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI ACWI ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index is a free float-adjusted market capitalization index designed to measure the combined equity market performance of developed and emerging markets countries.
Read more on ACWI →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
